EVENTS | VIEW CALENDAR
Agilent joins Applied Proteomics in mass spec deal
SANTA CLARA, Calif.—Agilent Technologies Inc. and Applied Proteomics Inc. have joined forces to collaborate on highly multiplexed protein assays and workflow solutions for multiple-reaction monitoring via mass spectrometry. The partnership unites Agilent's vast product offering in measurement tools and mass spectrometry equipment with Applied Proteomics' proteomics platform solution, which is based on computational expertise and mass spectrometry-based systems control.
"We are thrilled to be collaborating with Applied Proteomics, an organization that has leading expertise in developing mass spectrometry-based methods and instrumentation technologies for protein quantification and proteome applications," Can Ozbal, director of Agilent's RapidFire business, said in a press release. "Agilent's innovative automation, measurement and software platforms transform complete workflow solutions from sample preparation through data acquisition, analysis and evaluation in quantitative proteomics and biomarker validation."
In this undertaking, Applied Proteomics will make use of Agilent's 6490 Triple Quadrupole MS/MS, 1290 Infinity LC, RapidFire 360 MS system and Bravo liquid- handling technologies in order to optimize throughput in highly multiplexed proteomic assays. No financial terms regarding the collaboration were disclosed.
"The ability to quickly and accurately measure, monitor and analyze a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics. Agilent's innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays, " John E. Blume, Ph.D., chief science officer of Applied Proteomics, noted in a statement.
The partnership comes just a few weeks after Agilent announced another mass spectrometry-based agreement with Florida International University. The company will be collaborating with the University's department of chemistry and biochemistry and its International Forensics Research Institute to advance approaches for identifying and characterizing designer drugs. Agilent and Florida International University will seek to develop and validate new methods for rapid forensic screening and analysis utilizing advanced chromatography and mass-spectrometry systems such as LC-QQQ-MS/MS, LC-QTOF-MS, GC/MS and GC/MS/MS.
Designer drugs consist of novel analogs or derivatives of unlawful drug compounds synthesized to mimic illegal recreational drugs, and include classes such as phenethylamines, cathinones, tryptamines, piperazines and synthetic cannabinoids.
"Since routine immunoassay drug-screening methods are unable to detect most of the hundreds of individual designer drugs that have been identified, we are working with Agilent to develop advanced analytical methods to screen and confirm the presence of such drugs in both ante- and post-mortem specimens," Dr. Anthony DeCaprio, associate professor and director of the Forensic & Analytical Toxicology facility at Florida International University's International Forensic Research Institute, said in a press release regarding the collaboration. "Recently, we validated a method for the detection and quantification of 32 designer drugs in serum, including 24 phenethylamines, four piperazines and four tryptamines. In collaboration with Agilent, we will continue to expand our tandem mass-spectral library to approximately 300 designer drugs."
SOURCE: Agilent press release